06.08.2019 • News

Merck KGaA and Universal Display Link on OLEDS

Germany’s Merck KGaA has signed an R&D pact with US-based Universal Display...
Germany’s Merck KGaA has signed an R&D pact with US-based Universal Display Corporation (UDC) to cooperate on developing new products and further advance OLED displays. © Oleksiy Mark/Shutterstock

German chemicals and pharmaceuticals group Merck KGaA has signed an R&D agreement with Ewing, New Jersey-based Universal Display Corporation (UDC) to cooperate on developing new products and further advancing OLED displays.

The joint development program will bring together the US company’s expertise in leading-edge phosphorescent OLED emitters and Merck’s state-of-the-art transport materials, with the goal of developing higher performing OLED stacks for OLED manufacturers worldwide.

UDC’s Universal’s PHOLED technology and materials are designed to enable energy-efficient displays and lighting.

Kai Beckmann, CEO Performance Materials and member of the Executive Board of Merck, said the two partners “bring a perfectly matching set of know-how to the table” that will “greatly support” the Darmstadt-based liquid crystals giant in supplying its customers.

New insights gained during the collaboration will also help to “further advance and increase the performance of OLED technology in general, one of the most promising fields for the display industry,” Beckmann said.

Steven V. Abramson, president and CEO of the New Jersey company, said the research pactl with Merck will “help expand the landscape of bright, beautiful, brilliant OLED displays in the marketplace.”

Under a long standing agreement dating back to 2000, UDC’s PHOLED-based products are exclusively produced by paints and coatings manufacturer PPG at its plants in Monroeville, Pennsylvania, and Barberton, Ohio, manufacturing facilities.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read